Drug Trial Radar · NCT02629822
Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)
Last checked: Nov 19, 2026Latest source record: Oct 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jan 14, 2016
Primary completion
Nov 28, 2018
Study completion Oct 28, 2020
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Dec 14, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to evaluate the antiretroviral activity and the safety/tolerability of open-label doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF; MK-1439A; DELSTRIGO™) consisting of a single fixed-dose combination (FDC) tablet of DOR/3TC/TDF 100 mg/300 mg/300 mg in treatment-naïve HIV-1 infected participants with select non-nucleoside reverse transcriptase inhibitor (NNRTI) transmitted resistance-associated mutations.
Conditions
- HIV-1 Infection
Interventions
Doravirine/lamivudine/tenofovir disoproxil fumarateDrug
FDC tablet containing MK-1439 (doravirine) 100 mg / lamivudine 300 mg / tenofovir disoproxil fumarate 300 mg taken by mouth.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL of Plasma at Week 48Time frame: Week 48
- Percentage of Participants Experiencing ≥1 Adverse Events (AE) up to Week 48Time frame: Up to Week 48
- Percentage of Participants Who Discontinued Treatment Due to an AE up to Week 48.Time frame: Up to Week 48
- Percentage of Participants Experiencing ≥1 Adverse Events (AE) up to Week 96Time frame: Up to Week 96
- Percentage of Participants Who Discontinued Treatment Due to an AE up to Week 96Time frame: Up to Week 96
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.